ttIL12-T cells

ttIL12-T cells are an experimental adoptive T-cell therapy consisting of T cells engineered to express a tumor-targeted interleukin-12 (IL-12) construct. Developed by researchers at MD Anderson Cancer Center and the University of North Carolina at Chapel Hill, this therapy aims to overcome the toxicity associated with systemic IL-12 administration while maintaining its potent antitumor activity against solid tumors. The ttIL12 component is designed to target cell-surface vimentin (CSV), a marker often found on the surface of tumor cells but not normal cells. Upon binding to CSV in the tumor microenvironment, the ttIL12-T cells are stimulated to produce high levels of inflammatory cytokines such as IFNγ, Flt3L, and GM-CSF. This localized cytokine production triggers dendritic cell maturation, promotes tumor antigen spreading, and activates secondary T-cell responses, effectively eliminating large and heterogeneous solid tumors like osteosarcoma and melanoma in preclinical models.

Other names

tumor-targeted IL-12-armed T cellsttIL12-armed T cellsttIL-12-armed T cellsttIL 12-armed T cells